Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 37

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 37
---
 pursuant to this prospectus by the Selling Securityholder represent approximately 80.89% of shares of fully-diluted Common Stock outstanding as of November 24, 2025, assuming and after giving effect to the conversion of all outstanding Preferred Shares, the exercise of all outstanding Warrants and options, and options available for issuance pursuant to our 2024 Plan and 2024 ESPP Plan, as amended from time to time, of which 172,241,636 shares were held by non-affiliates (without taking into account beneficial ownership or stock exchange limitations). After the registration statement of which this prospectus forms a part is effective and until such time that it is no longer effective, it will permit the resale of these shares of Common Stock. The resale, or expected or potential resale, of a substantial number of shares of our Common Stock in the public market could adversely affect the market price for our Common Stock and make it more difficult for you to sell your holdings at times and prices that you determine are appropriate. Furthermore, we expect that, because there is a large number of shares of our Common Stock being registered pursuant to the registration statement of which this prospectus forms a part, the Selling Securityholder thereunder will continue to offer the securities covered thereby for a significant period of time, the precise duration of which cannot be predicted. Accordingly, the adverse market and price pressures resulting from an offering pursuant to the registration statement may continue for an extended period of time. Sales of substantial number of such shares in the public market, including the resale of the shares of Common Stock held by the Selling Securityholder, could adversely affect the market price of our Common Stock. In addition to this prospectus, we have filed:

| ● | a registration statement with the SEC for purposes of registering the resale from time to time of up to 105,000 Shares of Common Stock, which consists of (i) 104,318 shares of Common Stock under the March 2024 Keystone Purchase Agreement and (ii) 682 shares of Common Stock under the February 2024 Keystone Purchase Agreement; |

| ● | a registration statement with the SEC for purposes of registering the resale from time to time of up to 13,310 Shares of Common Stock, which consists of (i) 12,500 Keystone Purchase Shares, (ii) 310 Keystone Commitment Shares, and (iii) 500 Arena Commitment Shares; |

13

| ● | a registration statement with the SEC for purposes of registering (1) the resale from time to